Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine–venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net

Documenti analoghi

• Pharmacokinetic Boosting of Kinase Inhibitors
  di: Niels Westra, et al.
  Pubblicazione: (2023-04-01)
• Loss of quiescence and impaired function of CD34+/CD38low cells one year following autologous stem cell transplantation
  di: Carolien M. Woolthuis, et al.
  Pubblicazione: (2013-12-01)
• A single center analysis of nucleophosmin in acute myeloid leukemia: value of combining immunohistochemistry with molecular mutation analysis
  di: Carolien M. Woolthuis, et al.
  Pubblicazione: (2013-10-01)
• Advances and challenges in immunoPET methodology
  di: Philipp Mohr, et al.
  Pubblicazione: (2024-02-01)
• In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment
  di: Sietske B.M. Gaykema, et al.
  Pubblicazione: (2014-07-01)